X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/09/28/2524126/28235/en/Cornerstone-Pharmaceuticals-Initiates-Phase-1-Trial-of-CPI-613-devimistat-in-Combination-with-Chemoradiation-for-the-Treatment-of-Advanced-Pancreatic-Cancer.html
https://www.globenewswire.com/news-release/2022/06/27/2469477/28235/en/Cornerstone-Pharmaceuticals-to-Present-Pancreatic-Cancer-Data-on-CPI-613-Devimistat-From-Its-Open-Label-Phase-1-Study-at-the-European-Society-of-Medical-Oncology-ESMO-World-Congres.html
https://www.globenewswire.com/news-release/2022/06/16/2464300/28235/en/Cornerstone-Pharmaceuticals-Announces-Published-Data-on-CPI-613-Devimistat-as-an-Effective-Approach-to-Targeting-Carcinoma-Catabolism-UPDATE.html
https://www.globenewswire.com/news-release/2022/05/24/2449592/28235/en/European-Medicines-Agency-Grants-Orphan-Drug-Designation-to-Cornerstone-Pharmaceuticals-CPI-613-Devimistat-for-Treatment-of-Patients-with-Advanced-Unresectable-Biliary-Tract-Cancer.html
https://www.globenewswire.com/news-release/2022/01/18/2368484/28235/en/Rafael-Pharmaceuticals-Announces-Ongoing-Successful-Enrollment-and-Opening-of-Additional-Sites-for-Phase-2-Clinical-Trial-of-CPI-613-Devimistat-in-Combination-with-Gemcitabine-and-.html
https://www.globenewswire.com/news-release/2022/01/06/2362450/28235/en/Rafael-Pharmaceuticals-Announces-Successful-Completion-of-Dose-Escalation-with-No-Dose-Limiting-Toxicity-DLT-in-First-Cohort-of-APOLLO-613-Phase-1-2-Clinical-Trial-of-CPI-613-Devim.html
https://www.globenewswire.com/news-release/2021/11/11/2332725/28235/en/Rafael-Pharmaceuticals-Announces-First-Patient-Enrolled-in-APOLLO-613-Phase-1-2-Clinical-Trial-of-CPI-613-Devimistat-in-Patients-with-Relapsed-Clear-Cell-Sarcoma.html
https://www.marketwatch.com/story/rafael-pharma-shares-down-75-after-pancreatic-cancer-trial-didn-t-meet-primary-endpoint-271635424625
https://www.globenewswire.com/news-release/2021/10/28/2322588/0/en/Rafael-Holdings-Provides-Update-on-Rafael-Pharmaceuticals-Two-Phase-3-Trials-of-CPI-613-Devimistat-AVENGER-500-in-Metastatic-Pancreatic-Cancer-and-ARMADA-2000-in-Relapsed-or-Refrac.html
https://www.globenewswire.com/news-release/2021/07/01/2256444/28235/en/Rafael-Pharmaceuticals-Announces-Positive-Preplanned-Interim-Futility-Analysis-of-Pivotal-Phase-3-Trial-ARMADA-2000-of-CPI-613-Devimistat-for-Relapsed-or-Refractory-Acute-Myeloid-L.html
https://www.globenewswire.com/news-release/2021/06/30/2255603/28235/en/Rafael-Pharmaceuticals-to-Present-Pancreatic-Biliary-Tract-Cancer-Data-on-CPI-613-Devimistat-from-its-Multicenter-Randomized-Phase-1b-2-Trials-at-the-2021-European-Society-of-Medic.html
https://www.globenewswire.com/news-release/2021/06/29/2254976/28235/en/FDA-Grants-Rafael-Pharmaceuticals-Orphan-Drug-Designation-for-CPI-613-Devimistat-for-Treatment-of-Biliary-Cancer.html
https://www.cancernetwork.com/view/fda-grants-fast-track-designation-to-devimistat-for-treatment-of-aml
https://www.outsourcing-pharma.com/Article/2020/12/10/Rafael-Pharmaceuticals-cancer-drug-lands-FDA-orphan-status
http://www.globenewswire.com/news-release/2020/12/01/2137778/0/en/Rafael-Pharmaceuticals-Partners-with-Sara-s-Cure-and-SARC-for-the-Launch-of-Phase-2-Clinical-Trial-for-CPI-613-devimistat-in-Combination-with-Hydroxychloroquine-for-Patients-with-C.html
https://www.globenewswire.com/news-release/2020/11/10/2123878/0/en/Rafael-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-CPI-613-devimistat-for-the-Treatment-of-Pancreatic-Cancer.html
https://www.targetedonc.com/view/fda-grants-orphan-drug-designation-to-devimistat-for-soft-tissue-sarcoma
https://www.globenewswire.com/news-release/2020/10/27/2115194/0/en/Rafael-Pharmaceuticals-Crosses-Enrollment-of-100th-Patient-in-Pivotal-Phase-3-Trial-ARMADA-2000-of-CPI-613-Devimistat-for-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-AML.html
https://www.globenewswire.com/news-release/2020/08/06/2074264/0/en/Rafael-Pharmaceuticals-Achieves-Target-Enrollment-of-500-Patients-in-Pivotal-Phase-3-Trial-AVENGER-500-of-CPI-613-%EF%B8%8F-devimistat-for-Patients-with-Metastatic-Pancreatic-Cancer.html
https://www.globenewswire.com/news-release/2020/07/21/2064943/0/en/Rafael-Pharmaceuticals-Crosses-Midpoint-of-Enrollment-to-First-Interim-Analysis-in-Pivotal-Phase-3-Trial-ARMADA-2000-of-CPI-613-Devimistat-for-Relapsed-or-Refractory-Acute-Myeloid-.html
https://www.globenewswire.com/news-release/2020/05/26/2038661/0/en/Rafael-Pharmaceuticals-to-Present-Phase-1-Data-on-CPI-613-Devimistat-in-Patients-with-Locally-Advanced-or-Metastatic-Pancreatic-Cancer-at-American-Society-of-Clinical-Oncology-ASCO.html
https://www.globenewswire.com/news-release/2020/05/07/2029480/0/en/Rafael-Pharmaceuticals-Announces-In-Vivo-Study-to-Evaluate-the-Effects-of-CPI-613-Devimistat-in-Combination-with-Azacitidine-and-Venetoclax-on-Acute-Myeloid-Leukemia-Models.html
https://www.globenewswire.com/news-release/2020/04/28/2023410/0/en/Generex-Subsidiary-NuGenerex-Immuno-Oncology-Announces-Publication-of-Positive-Results-of-the-AE37-Phase-IIb-Breast-Cancer-Trial.html
https://www.globenewswire.com/news-release/2020/04/23/2020972/0/en/Rafael-Pharmaceuticals-Receives-Approvals-to-Open-Trial-Sites-in-India-and-Canada-for-Pivotal-Phase-3-Trial-ARMADA-2000-of-CPI-613-devimistat-in-Patients-with-Relapsed-or-Refractor.html
Market Place
Share 
